BPC-157
A stable gastric pentadecapeptide with an extraordinary preclinical record for tissue repair across tendon, gut, nerve, and vascular tissue — and almost no controlled human trials.
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a body protection compound originally isolated from human gastric juice. Across more than 200 rodent and in vitro studies — the majority from Predrag Sikirić's group at the University of Zagreb — it consistently accelerates healing of tendon, ligament, muscle, gut lining, nerve, and vascular tissue, apparently by upregulating angiogenesis, growth hormone receptor expression, and the nitric oxide system. Despite this deep preclinical base, controlled human efficacy trials do not exist, and BPC-157 is not approved for human use in any major jurisdiction.
Class
Synthetic stable gastric pentadecapeptide (15 amino acids)
Half-life
~4 hours subcutaneous (estimated from animal pharmacokinetic data); short (minutes) intravenous; ~1-2 hours oral
Routes
Subcutaneous, Oral, Intraperitoneal, Intravenous, Intranasal
Category
Healing & Recovery
Researched benefits
What it's studied for
Tendon and ligament repair
The most-studied application: rodent studies of transected Achilles tendons show BPC-157-treated animals with superior biomechanical tendon strength at 14 days versus controls, attributed to upregulated growth hormone receptor expression and fibroblast proliferation (PMID 30915550, 25415472). Human tendon-repair trials do not yet exist, so this remains preclinical inference.
Gut and gastrointestinal healing
Among the strongest signals in the dataset. Animal models show protection against NSAID-induced and ethanol-induced gastric lesions and healing in inflammatory bowel / colitis analogs (PMID 29898088). BPC-157's stability in gastric acid supports oral dosing for gut-specific conditions, and it is the peptide the FDA's July 2026 PCAC review is evaluating for ulcerative colitis.
Angiogenesis and wound healing
BPC-157 promotes new blood vessel formation at injury sites via VEGF/VEGFR2 upregulation and activation of the EGR-1 and FAK-paxillin wound-healing pathways (PMID 36416831, 21524250), which underlies much of its broad tissue-reparative activity.
Nitric oxide system modulation and vascular protection
A central integrative mechanism: BPC-157 stabilizes the NO system bidirectionally, protecting against vascular injury and ischemia-reperfusion damage. In human internal mammary artery tissue it produced endothelium-dependent, NO-mediated vasorelaxation (PMID 42123221).
Neuroprotection
Rodent studies show protective effects in dopaminergic and serotonergic neurotoxicity models and in traumatic brain injury and sciatic nerve models (PMID 21524250). Replication is limited and there is no human data, so this application is early and exploratory.
Anti-inflammatory activity
Documented across animal models via modulation of COX-2 and NF-κB pathways and suppression of inflammatory cytokine expression, contributing to reduced tissue damage in injury and ischemia models.
Mechanism
How it works
BPC-157 is a fragment of a larger body protection compound found in human gastric juice, and its defining property is stability: it resists hydrolysis by gastric acid and digestive enzymes, which differentiates it from most bioactive peptides and enables measurable systemic effects even after oral administration. Its actions appear multi-pathway rather than tied to a single receptor.
The most consistently described mechanism is promotion of angiogenesis. In preclinical injury models BPC-157 upregulates VEGF and VEGFR2 and accelerates new blood vessel formation at damaged sites, improving vascular remodeling during muscle and tendon healing. In parallel it upregulates growth hormone receptor expression in tendon fibroblasts, potentiating GH-stimulated cell proliferation through JAK2 signaling and enhancing local GH/IGF-1 signaling.
A second integrative mechanism is bidirectional modulation of the nitric oxide (NO) system. BPC-157 appears to stabilize NO signaling, counteracting both excess and deficiency, which links its cytoprotective, vasoprotective, and anti-inflammatory effects. Endothelium-dependent, NO-mediated vasorelaxation has been demonstrated in isolated human arterial tissue. It also activates wound-healing signaling through the EGR-1 and FAK-paxillin pathways and reduces inflammation via COX-2 and NF-κB modulation.
Animal work additionally suggests systemic effects through the brain-gut axis and modulation of dopaminergic and serotonergic systems, which is proposed to explain neuroprotective and CNS-related signals. Importantly, essentially all of this mechanistic detail derives from rodent and in vitro studies — human pharmacokinetic and pharmacodynamic characterization remains a recognized gap, and a 2026 review noted a disconnect between the peptide's PK/PD properties that has impeded clinical advancement.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as a lyophilized powder reconstituted with bacteriostatic water. A common preparation adds 2 mL BAC water to a 5 mg vial, giving 2500 mcg/mL — 250 mcg per 10 units (0.1 mL) on a 100-unit insulin syringe. Store lyophilized powder at -20°C in a desiccated environment; store reconstituted peptide refrigerated at 2-8°C and use within about 4 weeks (30 days).
Beginner
- Dose
- 250 mcg
- Frequency
- Twice daily (AM/PM)
- Timing
- Inject near the injury site if targeting localized repair
- Duration
- 4-6 weeks
- Route
- Subcutaneous
Week 1 often run once daily to assess tolerance before moving to twice-daily therapeutic dosing.
Intermediate
- Dose
- 500 mcg
- Frequency
- Twice daily
- Timing
- AM and PM for steadier serum levels; once daily acceptable
- Duration
- 6-8 weeks
- Route
- Subcutaneous
Frequently combined with TB-500 for enhanced tissue-repair synergy.
Advanced
- Dose
- 500-750 mcg
- Frequency
- Twice daily
- Timing
- AM and PM
- Duration
- 8-12 weeks
- Route
- Subcutaneous
Often stacked with TB-500 (2.5 mg 2x/week) and GHK-Cu for comprehensive healing protocols.
- Community protocols cluster around 200-500 mcg subcutaneously 1-2x daily; animal studies used roughly 1-10 mcg/kg. Dosing is typically a flat dose rather than weight-based.
- Cycle length is commonly 4-12 weeks (8 weeks most common); some run 4 weeks on / 2 weeks off.
- Oral capsules (often 500 mcg) are favored for gut-specific applications because the peptide contacts damaged GI tissue directly and resists gastric degradation; injectable routes are preferred for systemic targets such as tendon, ligament, nerve, and muscle repair.
- No human clinical trial has validated any dosing regimen for BPC-157 for any route; all protocols derive from preclinical models and research-community practice.
Evidence
Research & clinical studies (9)
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
Despite three decades of preclinical activity, BPC-157 remains early-stage with no approved formulation, no validated dosing regimen, and no completed Phase II trials, with PK/PD disconnects impeding clinical advancement.
PMID 42198317Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
BPC-157 produced concentration-dependent relaxation of human arterial tissue that was substantially reduced by nitric oxide synthase blockade, indicating an endothelial NO-dependent vasorelaxant mechanism.
PMID 42123221Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
BPC-157 reduced oxidative stress, suppressed inflammatory and apoptotic pathways, and preserved muscle architecture in a rat limb ischemia-reperfusion model.
PMID 42204242Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats — A Cytoprotection Approach
BPC-157 showed cytoprotective therapeutic effects in a rat unilateral adrenalectomy model.
PMID 42356491BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase
BPC-157 and hybrid analogs were characterized as acetylcholinesterase inhibitors, suggesting a mechanism relevant to neurological activity.
PMID 42278509Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
In rat Achilles tendon fibroblasts, BPC-157 dose- and time-dependently upregulated growth hormone receptor expression and potentiated GH-stimulated proliferation via JAK2 signaling.
PMID 25415472Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing
In rat crushed-muscle and transected-tendon models, BPC-157 upregulated VEGF and enhanced angiogenesis with more adequate vascular remodeling than controls.
PMID 20388964First human intravenous pilot safety study of BPC-157 (Lee et al.)
In a small cohort, escalating-dose IV BPC-157 produced no serious adverse events and no clinically significant laboratory changes, providing the first formal human safety signal though not powered for efficacy.
PMID 40131143Accelerated healing of transected rat Achilles tendon with BPC 157
BPC-157-treated rats showed superior biomechanical tendon strength at 14 days post-injury compared with controls.
PMID 30915550Combinations
Stacking & blends
Wolverine Stack (BPC-157 + TB-500)
Comprehensive injury recovery and tissue repair
The most widely referenced healing combination: BPC-157 drives local, angiogenic tendon/ligament/gut repair while TB-500 (thymosin beta-4 fragment) supports systemic actin assembly, cell migration, and broader tissue repair — complementary steps in the healing cascade with minimal mechanistic overlap.
BPC-157 + GHK-Cu
Wound healing and skin/dermal repair
Pairs BPC-157's deep-tissue and vascular repair signaling with GHK-Cu's copper-dependent collagen synthesis, antioxidant gene activation, and extracellular matrix remodeling, addressing both structural integrity and surface skin quality.
CJC-1295 + Ipamorelin + BPC-157
Recovery plus growth hormone support
Combines GH-secretagogue synergy (CJC-1295 + Ipamorelin) for protein synthesis, body composition, and systemic recovery with BPC-157's targeted tissue repair and anti-inflammatory effects — used by athletes seeking anabolic support alongside injury recovery.
GLOW Blend
Multi-tissue repair, angiogenesis, and skin quality
A three-component research blend proposing additive tissue-reparative signaling: BPC-157 via NO modulation and GH-receptor upregulation, TB-500 via actin/cell migration, and GHK-Cu via collagen and antioxidant pathways.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer or history of cancer (theoretical concern given angiogenic properties)
- Pregnancy or breastfeeding
- Concurrent anticoagulant / blood-thinner use (possible platelet and vascular effects — monitor)
- Active infection where increased blood flow could theoretically spread pathogens
Preclinical safety is favorable — no LD50 or organ toxicity established at supratherapeutic doses in rodents — and a 2025 IV pilot reported no serious adverse events. However, long-term human safety is not characterized at Western RCT standards. A theoretical concern that angiogenic activity could support tumor angiogenesis has been raised but not clinically substantiated. In the research-peptide market, product identity, purity, sterility, and correct labeling (acetate vs free base) are real quality-control issues.
FAQ
BPC-157 — common questions
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a body protection compound found in human gastric juice. It is studied preclinically for tissue repair, gut healing, tendon and ligament recovery, and anti-inflammatory effects, and is sold as a research chemical with no FDA-approved human use.
Does BPC-157 actually work?
In rodents, the tissue-repair signal across tendon, ligament, gut lining, and vascular tissue is remarkably consistent across 200+ studies. In humans, controlled efficacy trials do not exist — the human record is limited to a small uncontrolled interstitial-cystitis pilot, a tiny IV safety pilot, and a recruiting hamstring-strain trial. Extrapolating the rat data to human injury repair is preclinical inference, not proven efficacy.
How is BPC-157 administered?
It is studied via subcutaneous injection (most common for systemic and localized musculoskeletal repair), oral capsules (favored for gut-specific conditions because it resists gastric degradation), and intraperitoneal, intravenous, and intranasal routes in various research contexts. No human dosing protocol is FDA-validated.
What is a typical research dose?
Community protocols commonly use roughly 250-500 mcg subcutaneously once or twice daily, often injected near the area of interest, in cycles of about 4-12 weeks. Animal studies used approximately 1-10 mcg/kg. Dosing is generally a flat dose rather than weight-based.
Is BPC-157 legal and FDA approved?
It is not FDA-approved for any indication and is sold as a research chemical, not a controlled substance in the US. It was removed from the FDA's Category 2 bulk substances list on April 22, 2026, with a Pharmacy Compounding Advisory Committee review set for July 23, 2026 evaluating ulcerative colitis — the most advanced regulatory pathway of any non-approved peptide. Human use outside clinical trials remains unapproved, and it is banned in competitive sport by WADA.
Does BPC-157 cause cancer?
A theoretical concern exists — because BPC-157 promotes angiogenesis, its vascular effects could in principle support tumor blood-vessel growth — but this has not been clinically substantiated, and long-term human surveillance has not been done at scale. Anyone with active cancer or a cancer history should consult a physician before considering it.
What are its side effects?
Reports are generally clean. The most common is mild injection-site soreness or redness; rare mild nausea with oral use and transient lightheadedness are also reported. A minority of community reports describe mood changes or anxiety. Long-term human safety is not established.
Should I stack BPC-157 with TB-500?
They are frequently run together as the 'Wolverine stack' because they act through different mechanisms — BPC-157 more local and angiogenic, TB-500 more systemic via actin regulation and cell migration. The rationale is complementary healing signaling, though no human trial has validated combination protocols.
